Podcasts about ALK

  • 279PODCASTS
  • 1,008EPISODES
  • 25mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Jun 16, 2025LATEST

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about ALK

Show all podcasts related to alk

Latest podcast episodes about ALK

GoodLIFE Radio
Hooikoorts beinvloed uitslagen eindexamen! - GoodLIFE Radio Update 16 juni 2025

GoodLIFE Radio

Play Episode Listen Later Jun 16, 2025 13:29


Terwijl in mei en juni de examens in volle gang zijn, ervaren veel jongeren tegelijkertijd de piek van het pollenseizoen. Naar schatting heeft 28% van de 15- tot 19-jarigen last van hooikoorts, en dat gaat niet ongemerkt voorbij. Uit onderzoek* van ALK blijkt dat 50% van de ouders denkt, dat de allergieklachten de examenprestaties van hun kind negatief beïnvloeden. Hooikoorts veroorzaakt klachten zoals niezen, een verstopte neus, jeukende ogen en slaapproblemen. Juist die verstoorde nachtrust baart ouders zorgen: meer dan 60% maakt zich zorgen over het slaapgebrek van hun kind en het effect daarvan op cognitieve prestaties.  Tieners hebben tussen de acht en tien uur slaap nodig om optimaal te kunnen functioneren tijdens examens”, zegt kinderarts-allergoloog Monique Gorissen. “Als die slaap wordt verstoord door allergieklachten, missen ze belangrijke diepe slaapfases die nodig zijn voor concentratie en geheugen. Presentator Ron Lemmens sprak met Medisch Directeur Elena Uss. Elena is een ervaren medisch professional met meer dan vijftien jaar ervaring in de farmaceutische industrie. Ze heeft verstand van medische zaken, klinisch onderzoek, recht- en regelgeving binnen de farmacie, market access en vergoedingsprocessen, en kent een grootnetwerk. Tijdens de non-stop uren op GoodLIFE Radio hoor je de meeste interessante updates over gezondheid en leven. Wat zijn de mooie initiatieven? Wat is er anders in deze onwerkelijke tijden? Laat het ons weten! De podcast is na de uitzending terug te luisteren via alle bekende podcast platforms (onder meer Spotify, Apple Podcasts en Google Podcasts).

Research To Practice | Oncology Videos
Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 10, 2025 58:22


Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics: Introduction: Actionable Genomic Alterations (0:00) ALK (9:49) ROS1 (22:22) HER2 (31:00) RET (38:52) NTRK (45:30) MET (46:31) Novel Targeted Strategies (49:09) BRAF (54:19) KRAS G12C (55:38) CME information and select publications

Treningspodden
Trening i pollensesongen – hva bør du vite?

Treningspodden

Play Episode Listen Later May 22, 2025 20:44


Vi har med oss legen Oscar Ohene Asante, Øre-nese-hals-spesialisten – og ikke minst en dedikert løper selv!Lyse morgener, grønne parker og nye treningsmuligheter lokker oss ut i det fri. Men for en pollenallergiker kan denne tiden på året kjennes mer som en kamp enn nytelse. Trøtthet, kløende øyne og rennende nese er ikke akkurat drømmeselskap på trening – så hvordan holder man koken uten at allergien får overtaket?I denne episoden av Treningspodden får du svaret! Oscar forklarer hva pollenallergi egentlig er, hvilke symptomer som er de vanligste – og viktigst av alt: hvordan du kan lindre plagene. God lytt! Denne episoden er laget i samarbeid med ALK – et globalt, forskningsdrevet selskap som jobber med forebygging, diagnostisering og behandling av allergi. ALK står også bak nettsiden pollenkontroll.no, hvor du finner nyttig informasjon og verktøy for å få bedre kontroll på hverdagen med pollenallergi. Hosted on Acast. See acast.com/privacy for more information.

Kutsal Motor
Son 25 Yılın 10 Hayal Kırıklığı, 19 Dakika Alkışlanan Film, Last of Us S2B6 | N'aber Sinema #55

Kutsal Motor

Play Episode Listen Later May 22, 2025 139:46


Her hafta Canlı Yayında sinema ve televizyon gündemini konuşuyoruz, ilgimizi çeken konuları tartışıyoruz.00:00 | Giriş07:15 | Mission: Impossible - The Final Reckoning26:20 | Murderbot28:10 | The Last of Us - S2E6 43:30 | Son 25 Yılın 10 Hayal Kırıklığı 1:19:45 | Güncel Cannes eleştiri tablosu1:39:30 | Cannes'da Ayakta En Çok Alkışlanan Filmler1:44:25 | Cannes Filmleri  1:47:55 | Sinema Gündemi: Haber Turu1:57:40 | Fatih Akın'ın Ayşe Barım Açıklaması 1:59:55 | Martin Scorsese Belgeseli Yolda2:00:00 | Jodie Foster'dan Genç Oyunculara Eleştiri2:05:05 | Damien Chazelle'in Yeni Filminin Kadrosu2:05:05 | Adam Curtis & A242:07:20 | David O. Russell ve Yine Olaylı seti2:08:05 | Blockbuster Filmler2:10:40 | MUBI'de Bu Hafta

Mevlana Takvimi
ZEHEBÎ'NİN İMÂM-I AZAM EBÛ HANÎFE (R.A.)'E ÖVGÜSÜ-17 MAYIS 2025-MEVLANA TAKVİMİ

Mevlana Takvimi

Play Episode Listen Later May 17, 2025 2:56


Hadîs ricâlini tenkîd noktasında büyük bir otorite olan (ehlü'l-istikrâ) Zehebî'nin söylemiş olduğu en doğru sözlerden birisi, Siyer-u A'lamî'n-nübelâ isimli eserinde Irak'ın fakihi Allâme İmâm Hammad b. Ebû Süleyman (r.âleyh)'in hayat hikâyesini aktarırken kullanmış olduğu şu ifâdelerdir: “Kûfelilerin en fakihi Hz. Alî (r.a.) ve İbn Mes'ûd (r.a.)'dir. Bu iki sahâbenin en fakih öğrencileri Alkâme, Alkâme'nin en fakih öğrencisi İbrâhîm en-Nehaî, Nehâî'nin en fakih öğrencisi Hammad, Hammad'ın en fakih öğrencisi ise Ebû Hanîfe (r.a.)'dir. Ebû Hanîfe (r.a.)'in en fakih öğrencisi Ebû Yusuf'tur. Ebû Yusuf'un öğrencileri dünyanın dört bir tarafına yayılmışlardır. Bunların en fakihi Muhammed b. el-Hasen'dir. İmâm Muhammed'in en fakih öğrencisi ise Ebû Abdullah eş-Şâfiî'dir.Allâh (c.c.) tamâmına rahmet eylesin.” Zehebî aynı eserinin bir başka yerinde İmâm Ebû Hanîfe (r.a.)'in hayatını anlatırken şu ifâdeleri kullanmaktadır: “İmâm, dînin fakihi ve Irak'ın âlimi Ebû Hanîfe (r.a.)… Hadîs ilmine önem verdi. Bu uğurda yolculuklar yaptı. Fıkıh, rey ve reyin kapalı noktalarını tetkik etmede zirvedir. Bu konuda bütün insanlar ona minnet borçludur.” Zehebî aynı eserinin bir başka yerinde Ebû Hanîfe (r.a.) hakkında “Fıkıhta ve fıkhın inceliklerinde önde gelen bir âlim olduğu herkesçe kabûl edilen bir gerçektir. Bu noktada hiçbir kuşkuya yer yoktur” demektedir.(Muhammed Abdurreşid En-Nûmanî, İmâm-ı Azam Ebû Hanîfe (r.a.)'in Hadis İlmindeki Yeri, s. 44-45)BIR FIKIH KAIDESI ÖĞRENELIM!Bir kimse iki veya daha fazla secde ayetini aynı mecliste okusa veya secde ayetini okusa ve akabinde aynı yerde başka işle meşgul olsa, mesela birçok şey yese veya yatarak uyusa yahut da kadın ise bebeğini emzirse, sonra da yine aynı yerde aynı ayeti okusa iki kere secde etmesi gerekir.(Misvâk Neşriyat, Eşref Ali Et-Tehanevi, Hanefi İlmihali, s.211)

Oncology Brothers
Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations

Oncology Brothers

Play Episode Listen Later May 15, 2025 21:47


Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital. In this episode, we covered: •⁠  ⁠Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations. •⁠  ⁠The importance of comprehensive NGS testing and the need for retesting at progression. •⁠  ⁠Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities. •⁠  ⁠Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies. •⁠  ⁠The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. YouTube: https://youtu.be/LMYDAjZcn5w Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

Backstage @ Upstage
Living with ALK+: Diagnosis, Treatment, & Hope

Backstage @ Upstage

Play Episode Listen Later May 7, 2025 33:55


A Biomarker Dialogue Between Patient and Scientist HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Marc Muskavitch, PhD, ALK+ & Zachary Rogers, PhD, Research Fellow, Koch Institute at MIT This episode features a powerful conversation between two scientists, one now navigating life as a Stage 4 ALK+ lung cancer patient. Most lung cancer patients only learn … Continue reading Living with ALK+: Diagnosis, Treatment, & Hope →

Millionærklubben
Vindmøller, rengøring og udskiftning på ledelsesgangen i Coloplast

Millionærklubben

Play Episode Listen Later May 6, 2025 54:16


Fuld gang i rapporteringen fra de danske selskaber tirsdag, der bringer nyt fra Vestas, ISS, Coloplast, ALK, DFDS og - sidst på dagen - Demant. Millionærklubben tjekker stemningen og tager desuden en tur forbi oliepriserne, der efter sidste nyt fra OPEC+ viger i pris. I studiet: Lau Svenssen og Bodil Johanne Gantzel.See omnystudio.com/listener for privacy information.

Foreldrerådet
690. Har barnet mitt pollenallergi?

Foreldrerådet

Play Episode Listen Later May 5, 2025 36:38


Hvordan vet du om barnet ditt har pollenallergi – eller om det bare er en lang vårforkjølelse? Hva er første steg i behandling, og hva kan du gjøre i hverdagen for å lindre plagene?Barnelege og allergiforsker Tonje Reier-Nilsen forklarer hvordan pollenallergi kan påvirke barnets livskvalitet – og hvorfor tidlig diagnose og riktig behandling kan gjøre en stor forskjell.Episoden er laget i samarbeid med ALK, et forskningsdrevet legemiddelselskap som jobber med forebygging, diagnostisering og behandling av allergi – og driver nettsiden www.pollenkontroll.no. Hosted on Acast. See acast.com/privacy for more information.

Medicina por un tubo
Loida Zabala: Un reto paralímpico con cáncer de pulmón

Medicina por un tubo

Play Episode Listen Later May 5, 2025 28:15


Ostenta el récord de España de halterofilia en su categoría, ha participado en cinco juegos paralímpicos y su currículum en campeonatos de España, Europa y el mundo es interminable. Loida Zabala es todo un ejemplo de superación. Una mielitis transversa la hizo vivir en silla de ruedas y, a finales de 2023, fue diagnosticada de cáncer de pulmón ALK positivo. Eso no le impidió participar en los Juegos Paralímpicos de Londres. Loida nos cuenta su experiencia y cómo el deporte le ayuda en el día a día en un episodio en el que contamos con público en las oficias de Roche Farma España. 

The PQI Podcast
Season 8 Episode 12 : Lorlatinib in Practice: 5 Years of Data, Real-World Counseling, and AE Management

The PQI Podcast

Play Episode Listen Later May 1, 2025 56:46


Lorlatinib is reshaping first-line treatment for ALK-positive NSCLC—but its distinct side effect profile demands proactive, personalized management. In this episode,  Stefanie Houseknecht, PharmD, BCOP (Johns Hopkins Medicine) and Monica Chintapenta, PharmD, BCOP (Parkland Health)share how they're navigating real-world use of lorlatinib, from interpreting long-term data to counseling patients through CNS effects, weight gain, and metabolic challenges.Highlights:Why lorlatinib is gaining traction in first-line ALK+ NSCLCWhat the long-term CROWN data really means for patient outcomesHow to handle tricky side effects like cognitive changes, weight gain, and hyperlipidemiaReal-world tips for patient counseling and supporting adherenceThe importance of catching drug interactions and staying ahead on labsHow pharmacists are shaping care across the oncology teamBonus: Hear how our guests find balance beyond the clinic, whether in the garden or on the Boston marathon course. About Our Guests:Monica completed her Doctor of Pharmacy at Texas Tech University Health Sciences Center and went on to complete PGY-1 and PGY-2 residencies at Tufts Medical Center and Froedtert & the Medical College of Wisconsin, respectively. At Parkland, she supports outpatient hematology/oncology care and leads quality initiatives.   Stefanie earned her PharmD from the University of the Pacific, followed by PGY-1 and PGY-2 residencies at Palomar Medical Center and the University of California-San Diego. Her work focuses on thoracic malignancies, access to oral targeted therapies, and patient outcomes. She is active in the International Association for the Study of Lung Cancer and serves as a preceptor to pharmacy trainees across the Mid-Atlantic.  

A-kursen
Välkommen våren? (Extrakursen i pollenallergi)

A-kursen

Play Episode Listen Later May 1, 2025 44:53


Våren förknippas ofta med glädje och livslust men för en allt för stor del av befolkningen är det faktiskt tvärtom. För pollen försämrar livskvalitén för allergiker som blir mindre produktiva, sjuka och får svårt att delta i sociala aktiviteter. Fast såhär behöver det faktiskt inte vara, det finns hjälp att få mot pollenallergi. I extrakursen i pollenallergi berättar Victoria Strand, som är överläkare och specialist i allergisjukdomar, varför man inte ska trivialisera sin pollenallergi, vilka behandlingsformer det finns och hur kan man hjälpa barn med jobbiga symtom.Avsnittet är ett samarbete med ALK, ett globalt, forskningsdrivet företag som arbetar med prevention, diagnostisering och behandling av allergi. ALK driver också hemsidan Pollenkoll.se och appen Pollenkoll. Hosted on Acast. See acast.com/privacy for more information.

acast avsnittet alk pollenallergi
OncLive® On Air
S12 Ep38: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

OncLive® On Air

Play Episode Listen Later Apr 16, 2025 44:04


This PER® Spectives™ featured podcast reviews the 22nd Annual Winter Lung Cancer Conference® held in January/February 2025. Multiple successive generations of ALK inhibitors have provided increasing benefits as first-line treatment for the thousands of patients with non-small cell lung cancer (NSCLC) that harbors rearrangements or mutations in the ALK gene. This program focuses on the practical aspects of managing patients with ALK-positive advanced or metastatic NSCLC, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Research To Practice | Oncology Videos
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 10, 2025 57:29


Featuring an interview with Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:22) CME information and select publications

Lung Cancer Update
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor

Lung Cancer Update

Play Episode Listen Later Apr 10, 2025 57:28


Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.

Research To Practice | Oncology Videos
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 9, 2025 31:22


Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:31) CME information and select publications

Keeping Current CME
Best Practices for the Multidisciplinary Care of Patients With Early-Stage ALK-Positive NSCLC

Keeping Current CME

Play Episode Listen Later Mar 25, 2025 17:23


Are you up to date on the most optimal management of patients with early-stage ALK-positive non-small cell lung cancer (NSCLC)? Credit available for this activity expires: 3/24/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/preeclampsia-biomarker-screening-every-trimester-2025a100065r?ecd=bdc_podcast_libsyn_mscpedu

OncLive® On Air
S12 Ep28: Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD

OncLive® On Air

Play Episode Listen Later Mar 24, 2025 11:22


In today's episode, supported by Summit Therapeutics, we had the pleasure of speaking with Xiuning Le, MD, PhD, about the use of ivonescimab (SMT112) in patients with PD-L1–positive non–small cell lung cancer (NSCLC). Dr Le is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center in Houston. The phase 3 HARMONi-2 trial (NCT05499390) investigated ivonescimab vs pembrolizumab (Keytruda) in patients with locally advanced or metastatic, PD-L1–positive NSCLC without sensitizing EGFR mutations or ALK translocations. At the preplanned interim analysis, at a median follow-up of 8.7 months (IQR, 7.1-10.3), the median progression-free survival was significantly longer in the ivonescimab arm (n = 198) vs the pembrolizumab arm (n = 200), at 11.1 months (95% CI, 7.3-not estimable) vs 5.8 months (95% CI, 5.0-8.2), respectively (stratified HR, 0.51; 95% CI, 0.38-0.69; 1-sided P < .0001). The objective response rates were 50% (95% CI, 43%-57%) and 39% (95% CI, 32%-46%) in these respective arms. In our exclusive interview, Dr Le discussed the rationale for the HARMONi-2 trial, key findings from the study, and where these findings position the potential role of ivonescimab in the PD-L1–positive NSCLC treatment paradigm.

Ramt af livet
Ramt af luftvejsallergi: "Min læbe lignede botox-gone-wrong"

Ramt af livet

Play Episode Listen Later Mar 12, 2025 32:57


Luftvejsallergi kan forvandle hverdagen til en kamp mod kløende øjne, tilstoppet næse og åndenød. For nogle betyder det at sige farvel til sport, sociale arrangementer og endda kæledyr.20-årige Malou har kæmpet med pollen-, støv- og pelsallergi siden barndommen og ved, hvad det vil sige at få sin hverdag begrænset. Hør, hvordan hun har lært at navigere i allergien og finde strategier og behandlinger, der gør dagligdagen lettere.Podcasten er produceret af SundhedsTV og udgives i samarbejde med Helse. Afsnittet er sponsoreret af ALK. 

Zacks Market Edge
Screening for Value Stocks with the Powerful PEG Ratio

Zacks Market Edge

Play Episode Listen Later Mar 10, 2025 27:55


Tracey Ryniec, Zacks Value Stock Strategist, looks for stocks with high Zacks Rank and low PEG ratios. (0:30) - Can The PEG Ratio Help You Find Strong Value Stocks For Your Portfolio? (4:20) - Tracey's Top Stock Picks To Keep On Your Watchlist Right Now (24:30) - Episode Roundup: UAL, COOP, FOLD, ALK, AAL

Value Investor
Screening for Value Stocks with the Powerful PEG Ratio

Value Investor

Play Episode Listen Later Mar 10, 2025 27:55


Tracey Ryniec, Zacks Value Stock Strategist, looks for stocks with high Zacks Rank and low PEG ratios. (0:30) - Can The PEG Ratio Help You Find Strong Value Stocks For Your Portfolio? (4:20) - Tracey's Top Stock Picks To Keep On Your Watchlist Right Now (24:30) - Episode Roundup: UAL, COOP, FOLD, ALK, AAL Podcast@Zacks.com

THE EMBC NETWORK featuring: ihealthradio and worldwide podcasts
308. TANYA CARMONA DANIELS UPDATES US ABOUT CHLORINE DIOXIDE (CD)

THE EMBC NETWORK featuring: ihealthradio and worldwide podcasts

Play Episode Listen Later Mar 6, 2025 75:05


308. TANYA CARMONA DANIELS UPDATES US ABOUT CHLORINE DIOXIDE (CD) She is a top insider with the Andreas Kalcker Institute, his ALK foundation, and their international umbrella organization, COMUSAV. Support the show Writer | Robert Yoho author

THE EMBC NETWORK featuring: ihealthradio and worldwide podcasts
308. TANYA CARMONA DANIELS UPDATES US ABOUT CHLORINE DIOXIDE (CD)

THE EMBC NETWORK featuring: ihealthradio and worldwide podcasts

Play Episode Listen Later Mar 6, 2025 75:05


308. TANYA CARMONA DANIELS UPDATES US ABOUT CHLORINE DIOXIDE (CD) She is a top insider with the Andreas Kalcker Institute, his ALK foundation, and their international umbrella organization, COMUSAV. Support the show Writer | Robert Yoho author

NewsWare‘s Trade Talk
NewsWare's Trade Talk: Thursday, January 23

NewsWare‘s Trade Talk

Play Episode Listen Later Jan 23, 2025 19:27


S&P Futures are trading slightly lower this morning due to weakness in semiconductors. Markets are questioning the numbers and the timing of the recently announced Stargate Project. Key event today will be President Trump's speech today at Davos summit. Trump is schedule to speat at 11:00 am ET. His interview last night was rather uneventful as the focus was on his issues with former president Biden and FEMA. Central Bank meetings are on watch, the BOJ will make an announcement tomorrow, FOMC announcement on Jan 29th, and the ECB announcement is scheduled for Jan 30th. Earnings beats came in from ALK, DFS, GE, and MKC. After the bell today TXN and ISRG will report, and tomorrow morning AXP & VZ will report. European shares are mixed to higher & oil prices are higher by +0.50% this morning.

ASCO Guidelines Podcast Series
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer Guideline

ASCO Guidelines Podcast Series

Play Episode Listen Later Jan 9, 2025 16:25


Dr. Evan Yu presents the new evidence-based guideline on genetic testing for metastatic prostate cancer. He discusses who should receive germline and somatic testing with next-generation sequencing technologies, what samples are preferred for testing, and the therapeutic & prognosistc impacts of genetic testing. Dr. Yu emphasizes the need for awareness and refers to areas of active investigation and future research to improve personalized therapies for patients with metastatic prostate cancer.  Read the full guideline, “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline” at www.asco.org/genitourinary-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02608 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Evan Yu from the University of Washington and Fred Hutchinson Cancer Center, lead author on “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline”. Thank you for being here today, Dr. Yu. Dr. Evan Yu: Thanks for having me on. Brittany Harvey: Great. Then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the entire guideline, including Dr. Yu, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, Dr. Yu, to start us off on the content of this guideline, could you first provide an overview of both the purpose and scope of this guideline? Dr. Evan Yu: Yeah, absolutely. So I think the one key thing to recognize is that prostate cancer is the highest incidence of all cancers in males. Additionally, it's the second highest cause of mortality in males, and that's about 35,000 deaths in 2024. So with that being said and done, it's a disease where we need to do better. And part of that is recognizing that we now have many targeted therapies, precision medicine type of therapies, but unlike a lot of other cancers out there, prostate cancer patients are not always getting sequencing, next generation DNA sequencing, let's say, to identify both inherited and also spontaneously develop what we call somatic mutations in their tumor. And I suspect that's partially because other cancers like breast cancer, we're so used to- in the first line, you present the patient, you throw out their estrogen receptor status, progesterone receptor status, HER2, ER/PR HER2; in lung cancer it's EGFR, ALK, ROS1, etc. In things like prostate cancer, things like BRCA2 have major important patient treatment implications and potentially family counseling and downstream cascade testing implications. But it hasn't made their way into that first-line presentation yet. And for that reason, there are some studies out there that show that testing in the community may be as low as 15% of patients with metastatic prostate cancer. We want to bring awareness to that and hopefully increase testing down the road so that we can better help our patients with metastatic prostate cancer. Brittany Harvey: Absolutely. It's important to get these targeted therapies to the patients who can benefit most. Using that context, I'd like to next review the key recommendations of this guideline across the six clinical questions that the panel addressed. So, starting with: Who should receive germline testing with next generation sequencing technologies? Dr. Evan Yu: Yeah. We think that it's common enough that everyone with metastatic prostate cancer should receive germline genetic testing. And the reason for that is there have been studies that have looked at this and have shown that 12% of men with metastatic prostate cancer have some sort of inherited germline mutation in a gene, mostly DNA repair genes. But 12% have something that is inherited and that loved ones, first degree relatives, siblings, offspring might have also inherited. Now, most of these are in the DNA repair genes, but that being said and done, there's not only treatment implications for the patient, where there are newer drugs that that patient could get treated with, but other loved ones that might have inherited these gene mutations, that these things can cause other cancers as well - not just prostate cancer, but breast cancer, endometrial cancer, ovarian cancer, pancreatic cancer. So, it's very important to test, with as high of an incidence as 12%, to test, and if you identify it in a patient, it's our job to talk to the patient about it and talk to them about the pros and cons of family counseling and talking to their loved ones and potentially having their loved ones get tested. Because if they test positive, then their doctors may want to know and may screen them very, very aggressively and differently for a whole host of other cancers. And the whole idea is you find the cancer very early and cure the patients before the cancer really takes hold and has the ability to spread so we can save a lot of lives down the road. Brittany Harvey: Absolutely. This germline testing is important not just for the patient, but has wider implications for their families as well, as you mentioned. So then, beyond those recommendations for germline testing, which patients should receive somatic testing with next-generation sequencing technologies? Dr. Evan Yu: So let's talk a little bit about somatic testing. So germline again, as we know, is inherited. The patient inherited it in every single cell in their body, then it becomes very easy, many of these are cancer predispositions for them to lose the other allele and then to have biallelic loss and then develop the cancer. Now, somatic just means it spontaneously occurred. Certainly, it's not going to occur in every cell in the body, but you can get one hit, lose one allele and then lose the other allele. And if that gene is truly carcinogenic and leading to that cancer, then that can have implications potentially for treatment as well. So we recommend that all patients with metastatic prostate cancer also undergo somatic next-generation sequencing testing. We recognize that at this point in time it's only those with metastatic castration-resistant prostate cancer or hormone-resistant prostate cancer, which is a later disease state where there are drugs that may target those mutations, for instance, like PARP inhibitors, but that early identification for a patient population that's fit and that can benefit from these therapies makes sense so that you know it's in place already and you have your treatments outlined and mapped out for the future. So we recommend it for everybody - somatic testing also for everyone with metastatic prostate cancer. Brittany Harvey: Understood. And then when patients are receiving that somatic testing, what is recommended for somatic testing? Primary tumor archival tissue? Fresh metastatic biopsy tissue? Or circulating tumor DNA testing? Dr. Evan Yu: We recommend that in the initial setting when you're first diagnosed, that archival tissue samples are fine and preferred. But circulating tumor DNA is good when there's no accessible archival tissue, or if the archival tissue, let's say, is very old and it's been sitting around for a long time, or you can't get it anymore because it's many years back when maybe a patient had a prostate needle biopsy. So if it's not accessible, then we recommend ctDNA. We believe that is preferred and also that ctDNA is recommended in a situation where you can't easily biopsy a metastatic site. Sometimes it's just not in a safe area to go after. Sometimes it's just a small lesion. So in general, we recommend tissue when available, and when we think that the tissue sample will yield clean results, if not, then we recommend doing ctDNA at that point in time. Brittany Harvey: So you have described who should get germline and somatic genomic testing. But what are the therapeutic impacts of this germline or somatic testing for single gene genetic variants? Dr. Evan Yu: We pulled this panel together and we met like every single month for like 12 months straight, and part of it was to review the literature. And as part of this literature review, we were able to pull a whole bunch of different trials. I think there was like 1713 papers we identified in the literature search. Eventually, we narrowed it down because with ASCO, we want to present the data with the highest level evidence, level 1 evidence, randomized controlled prospective data. And after reviewing 1713 papers, we narrowed it down to 14 papers. With those 14 papers, if you look at it, there are a lot of things that we think may have implications for treatment or prognosis, but we didn't feel was the highest level of evidence that we could support. So the things that have the highest level of evidence that we can support are certain DNA repair gene alterations, especially BRCA2, and treatment with PARP inhibitors because there are many PARP inhibitor prospective trials that show progression-free survival benefit and even overall survival benefit. And so that's the type of study that achieved the level of evidence that we could include. So I would say BRCA1 and BRCA2 highest level of evidence and PARP inhibitor use also is included in that. Brittany Harvey: Understood. I appreciate you reviewing those therapeutic options. So then, the last clinical question, which you just touched on briefly, but what are the prognostic impacts of germline and/or somatic testing? Dr. Evan Yu: Whenever you do testing, especially if you use panel testing, you find a lot of information. There's a lot of different mutations and some of which are VUSs (variants of unknown significance) where we don't quite know what it means yet, but we can track that, especially if it's germline. But with somatic, we find lots of things that have implications, but maybe just not treatment implications. A perfect example is p53. p53 is one of the most common tumor suppressor gene mutations on all cancers, but in prostate cancer they can occur and they can usually occur late, although there can even be germline inherited p53 alterations. There's no treatment that targets p53 right now, but we know that if you have a p53 mutation that those patients may have more aggressive disease and that prognostic information is important to give to the patient. And I think it's important for future clinical trial design and direction. So we do not recommend making treatment recommendations or changes based on these prognostic only biomarkers at this point in time. But we do recommend that, based on this, we can design intensification trials for those patients who have these poor risk biomarkers and de-intensification trials for patients who may have a good risk biomarker. So for instance, SPOP is a gene where we think these patients may have better outcomes, they might respond better to certain hormonal therapies like abiraterone. I say might because the level of evidence isn't quite there. But what I would say is that these prognostic only biomarkers, we just don't think they cut the mustard yet to be able to make treatment decisions. But we do think that they can drive counseling for the patient and potential selection and trial design for the future to say, “Okay. This is a patient population that has a more aggressive cancer. We need to be more aggressive in treating these patients.” “This patient population might have a less aggressive cancer. Maybe we can de-intensify and say side effects and quality of life may be better for the patients.” Brittany Harvey: Definitely. It's important for thinking through how to personalize care for these patients. So then you've talked about this a little bit in talking through the recommendations, but could you expand on what is the importance of this guideline and how it will impact both clinicians and patients with metastatic prostate cancer? Dr. Evan Yu: Yeah, I think the number one thing is awareness. I think the data's out there and people that are in my field, they know this. But by evidence of the fact that it's not first-line presentation lingo that everyone's talking about things like BRCA status, it means it hasn't necessarily disseminated all the way through. So it's increasing awareness of the fact that both germline and somatic alterations can occur and that these may have impacts on the patient for their treatment and their prognosis, and basically to increase testing for the future. I really think that in the future, there'll be other reasons that we may want to serially even retest and we may find that there may be mutations that develop as mechanisms of resistance that might guide therapy down the road. So we need to get people to start doing this for everyone with metastatic prostate cancer, because someday we might be doing it not just once, but over and over again. Brittany Harvey. Absolutely. We hope this guideline reaches a wide audience and that these recommendations can be put into practice. Finally, you've talked about how not all the data in the field has yet risen to the level of evidence that made it into the guidelines. So what are the outstanding questions in future research areas for both germline and somatic genomic testing for metastatic prostate cancer? Dr. Evan Yu: It was in our discussion, but it clearly- it's not common enough for there to be randomized prospective trials that would reach that level of evidence to make it in this guideline recommendation. But we all know that for any solid tumor, you can get mismatched repair deficiency, microsatellite instability leading to hypermutation or high tumor mutational burden. And that happens in maybe 3 to 5% of patients with metastatic prostate cancer as well. There is evidence and data that these patients can potentially benefit from immunotherapies like pembrolizumab. But again, it's just not common enough for there to be those randomized prospective controlled trials out there. But we mention it because we know it's FDA-approved across all the tumor types, so we felt like we have to mention it because that's something that has treatment implications for the patient. But also, I alluded to this earlier, I think an area of active investigation is the tried and true number one driver of prostate cancer, which is androgen receptor. Testosterone binds to androgen receptors, stimulates it. That's how androgen deprivation therapy works. That's how abiraterone and the amides like enzalutamide, apalutamide, darolutamide, that's how they all work. But even beyond that, we're starting to identify that maybe 15%, 20% of patients with metastatic castration resistant prostate cancer have androgen receptor mutations. And there are newer classes of therapies like androgen receptor degraders like CYP11A1 antagonist that lead to complete adrenal annihilation of other steroid hormones that might promiscuously stimulate these androgen receptor mutants. These things develop as mechanisms of resistance, and in the future, we might want to serially test- and that's an active area of investigation in the future, to say you've been treated, let's say, with androgen deprivation therapy and abiraterone for years. There are certain mutations that might develop as a resistance mechanism. We might need to serially test somebody because you didn't have that mutation earlier on, but later in the disease course you might. And then there might be a new drug X out there that we would want to use. Again, we need the data, we need the randomized prospective controlled trials, but they're happening out there. And somewhere down the road we may rewrite this guideline and have a lot more recommendations to add to it. Brittany Harvey: Yes, we'll look forward to more research in this field to better provide targeted therapies for patients with metastatic prostate cancer across the treatment paradigm. And we'll look forward to report outs from those trials that you mentioned. So I want to thank you so much for your work to develop this guideline and thank you for your time today, Dr. Yu. Dr. Evan Yu: Thank you so much. It's wonderful to be here today. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

ReachMD CME
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 0.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-alk-inhibition-into-early-stage-nsclc-integrating-biomarker-driven-therapies-to-reduce-recurrence-risk-post-resection/27056/ This animated podcast explores the evolving role of ALK inhibitors in managing early-stage non-small cell lung cancer (NSCLC). Dr. Mark Socinski discusses molecular profiling as a cornerstone for identifying ALK fusion–positive cases and highlights clinical data from pivotal trials. He also addresses the challenges of treatment adherence, toxicity management, and the importance of surrogate endpoints in early-stage disease. The discussion concludes with key takeaways on integrating targeted therapies into standard care for early-stage resectable NSCLC.=

Lung Cancer Voices
Témoignage d'une patiente : Julie Desjardins

Lung Cancer Voices

Play Episode Listen Later Nov 26, 2024 25:29


La Dre Nathalie Daaboul s'entretient avec Julie Desjardins de la vallée d'Annapolis, en Nouvelle-Écosse, dans notre premier épisode du balado en français Voix du cancer du poumon. Julie lutte contre un cancer du poumon ALK+ de stade IV depuis qu'elle a reçu un diagnostic inattendu en juillet 2022, alors qu'elle n'avait que 39 ans. Elle fait part de son histoire inspirante et de la façon dont le cancer a changé sa vision de la vie dans cet épisode.

Summits Podcast
Epi 81: Fighting lung cancer with Betsy Beggs

Summits Podcast

Play Episode Listen Later Nov 19, 2024 47:44


In episode 81 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Betsy Beggs of Goldman Sachs. At 23 years old, Betsy was a young professional finding her footing in New York City when she was blindsided by a stage 4 ALK+ lung cancer diagnosis. Tune in as she bravely shares her cancer story. For more, listen to Sarah Beggs, Betsy's mother, share her story from a parent perspective: youtu.be/05CrU4ltf80

The Sunday Roast
S9 Ep30: Sunday Roast featuring Stefan Bernstein, CEO of GreenRoc Strategic Materials and Oliver Friesen, CEO of Guardian Metal Resources #GROC #GMET #SALT #ONDO #EML #ALK #ORCA #EPP #FRG #BZT #XTR #AFP #GLR #CEL #BSFA #GGP

The Sunday Roast

Play Episode Listen Later Nov 3, 2024 100:20


In this episode of the Sunday Roast, hosts Phil Carroll and Kevin Hornsby wrap up the week's big news, including Phil's recent trip to NYC amidst election buzz, the latest on Rachel Reeves' historic budget, and its impact on gilt yields and the UK economy. They're joined by Oliver Friesen, CEO of Guardian Metal Resources, to discuss Guardian's expansion with the Tempiute Tungsten Mine acquisition, and by Stefan Bernstein, CEO of GreenRoc Mining, who shares exciting updates on the Amitsoq Graphite Project and its role in Europe's EV supply chain. The team rounds off with market movers and shakers of the week. Tune in! 0:00 - 00:12:38 Weekly News Roundup  00:12:38 #GROC Interview 00:46:14 #GMET Interview 01:18:00 #SALT  01:18:10 #ONDO  01:18:24 #EML  01:18:55 #ALK  01:19:12 #ORCA 01:19:24 #EPP   01:21:18 #FRG  01:22:58 #BZT  01:25:11 #AFP  01:26:19 #XTR  01:26:40 #GLR  01:29:03 #CEL  01:32:38 #BSFA  Disclaimer & Declaration of Interest The information, investment views, and recommendations in this podcast are provided for general information purposes only. Nothing in this podcast should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion

Keeping Current CME
Medscape Onsite: Riding the Wave of NSCLC Updates From San Diego

Keeping Current CME

Play Episode Listen Later Oct 21, 2024 45:19


Do you know the latest data on EGFR-mutated and ALK-positive non-small cell lung cancer (NSCLC)?   Credit available for this activity expires: 10/16/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001752?ecd=bdc_podcast_libsyn_mscpedu

Research To Practice | Oncology Videos
Peripheral T-Cell Lymphoma | Oncology Today with Dr Neil Love: Peripheral T-Cell Lymphoma

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 17, 2024 46:17


Featuring an interview with Dr Steven Horwitz, including the following topics: Overview of peripheral T-cell lymphomas (PTCLs) (0:00) Efficacy and safety of brentuximab vedotin in the management of treatment-naïve and relapsed PTCLs (9:57) Emerging therapeutic strategies for PTCLs (19:48) Case: A man in his early 50s with CD30-positive anaplastic large cell lymphoma who experienced complete response (CR) to BV-CHP and continued remission after consolidation with autologous stem cell transplant (ASCT) (25:53) Management of ALK-positive anaplastic large cell lymphoma (32:14) Case: A man in his late 50s with CD8-positive PTCL not otherwise specified who achieved CR with CHOEP and experienced relapse after ASCT (34:33) Case: A woman in her early 70s with chemorefractory CD30-positive angioimmunoblastic T-cell lymphoma (38:26) Ongoing first-line studies for T-cell lymphomas; association of CAR T-cell therapy with T-cell malignancies (42:18) CME information and select publications  

OncLive® On Air
S11 Ep24: How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

OncLive® On Air

Play Episode Listen Later Oct 16, 2024 17:21


Dr Patil emphasized the significance of the phase 3 CROWN trial (NCT03052608), which compared lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with ALK-positive metastatic NSCLC. With a hazard ratio of 0.19 (95% CI, 0.13-0.27) for progression-free survival, the trial demonstrated lorlatinib's superior intracranial control and long-term efficacy compared with crizotinib, especially in patients with brain metastases. Drs Park and Patil also discussed challenges associated with managing lorlatinib-related toxicities, including mood changes, weight gain, and hyperlipidemia. Dr Patil suggested that starting at a lower dose and gradually escalating to the recommended dose could help mitigate some of these adverse effects and simultaneously maintain treatment efficacy. The conversation concluded with a shift towards the broader application of targeted therapies in earlier disease stages, drawing parallels between the phase 3 ALINA study (NCT03456076) in patients with ALK-positive

Lung Cancer Voices
ALK-Positive Lung Cancer: The 2024 Update

Lung Cancer Voices

Play Episode Listen Later Oct 9, 2024 34:39


In this episode, Dr. Paul Wheatley-Price sits down with Dr. Geoffrey Liu, Medical Oncologist at Princess Margaret Cancer Center and a Canadian leader in opening dozens of clinical trials. Dr. Liu gives a rundown of everything you need to know about ALK-positive lung cancer - what is ALK, how common is it, how this type of lung cancer is treated, and some of the most recent clinical trial updates.

Research To Practice | Oncology Videos
Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR | The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 8, 2024 58:14


Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Corey J Langer, including the following topics: Introduction: A Model for Targeted Treatment in Non-Small Cell Lung Cancer (NSCLC) (0:00) NSCLC with ALK, ROS1 and NTRK Rearrangements — Dr Langer (9:10) Current and Future Treatment of Metastatic NSCLC with RET, MET, HER2 and KRAS Alterations — Dr Dagogo-Jack (34:22) CME information and select publications

OncLive® On Air
S11 Ep20: FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC

OncLive® On Air

Play Episode Listen Later Oct 3, 2024 15:09


In today's episode, supported by AstraZeneca, we had the pleasure of speaking with Sandip P. Patel, MD, and Brendon M. Stiles, MD, about the FDA approval of perioperative durvalumab (Imfinzi) for patients with resectable non–small cell lung cancer (NSCLC). Dr Patel is a professor of medicine in the Department of Medicine at the University of California, San Diego. Dr Stiles is a professor of cardiothoracic surgery and chief of the Divisions of Thoracic Surgery and Surgical Oncology in the Department of Cardiothoracic & Vascular Surgery, as well as the associate director of Surgical Oncology at the Montefiore Einstein Comprehensive Cancer Center in Bronx, New York. On August 15, 2024, the FDA approved durvalumab plus platinum-containing chemotherapy in the neoadjuvant setting, followed by durvalumab monotherapy in the adjuvant setting, for the treatment of adult patients with resectable NSCLC with no known EGFR mutations or ALK rearrangements. This regulatory decision was backed by findings from the phase 3 AEGEAN trial (NCT03800134), in which the median event-free survival was not reached (95% CI, 31.9 months-not estimable [NE]) in patients who received the durvalumab regimen vs 25.9 months (95% CI, 18.9-NE) in those who received placebo plus chemotherapy (stratified HR, 0.68; 95% CI, 0.53-0.88; P = .0039). In our exclusive interview, Drs Patel and Stiles discussed the significance of this approval, key efficacy and safety findings from AEGEAN, and how the clinical use of perioperative treatment regimens reinforces the importance of involving multidisciplinary teams in every step of a patient's treatment plan.

Zacks Market Edge
How Many Stocks Should You Own?

Zacks Market Edge

Play Episode Listen Later Sep 27, 2024 31:03


Even though there are dozens of great value stocks, that doesn't mean you should own them all. (0:45) - Creating The Perfect Long-Term Portfolio: How Many Investments Should You Have? (9:00) - Tracey's Top Investments To Create A Manageable Individual Portfolio (27:20) - Episode Roundup: TAK, ALK, RNG

Value Investor
How Many Stocks Should You Own?

Value Investor

Play Episode Listen Later Sep 27, 2024 31:02


Even though there are dozens of great value stocks, that doesn't mean you should own them all. (0:45) - Creating The Perfect Long-Term Portfolio: How Many Investments Should You Have? (9:00) - Tracey's Top Investments To Create A Manageable Individual Portfolio (27:20) - Episode Roundup: TAK, ALK, RNG Podcast@Zacks.com

NewsWare‘s Trade Talk
NewsWare's Trade Talk: Thursday, September 12

NewsWare‘s Trade Talk

Play Episode Listen Later Sep 12, 2024 18:29


S&P Futures are displaying gains this morning as markets prepares for an ECB announcement on interest rates and this morning's data on Producer Prices. Jobless Claims are also on tap this morning, expectations are for a reading of 225,000. Tech stocks are showing gains. MRNA, NTGR and ALK, all released updated guidance data. After the bell today. ADBE is expected to release earnings. Norfolk Southern (NSC) is lower this morning as CEO was removed due to an improper relationship. An ECB announcement is expected at 8:15 am this morning. In Europe, markets are displaying strong gains, and oil prices are higher as Hurricane Francine is creating numerousness for oil futures.

CCO Oncology Podcast
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

CCO Oncology Podcast

Play Episode Listen Later Sep 6, 2024 13:53


In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLCPrevious TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases   Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLCThe global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC  Program faculty:Jessica J. Lin, MDAttending PhysicianMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsAlice T. Shaw, MD, PhDChief, Strategic PartnershipsAttending Physician, Thoracic OncologyDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsResources:To download the slides associated with this podcast discussion, please visit the program page.

CCO Oncology Podcast
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

CCO Oncology Podcast

Play Episode Listen Later Sep 5, 2024 13:46


In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLCLong-term safety observations for crizotinib and entrectinib CNS activity of entrectinib and repotrectinib in patients with brain metastasesRepotrectinib activity in ROS1-TKI resistance mutations  Program faculty:Jessica J. Lin, MDAttending PhysicianMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsAlice T. Shaw, MD, PhDChief, Strategic PartnershipsAttending Physician, Thoracic OncologyDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsResources:To download the slides associated with this podcast discussion, please visit the program page.

Summits Podcast
Epi 76: Facing your child's cancer diagnosis with Sarah Beggs

Summits Podcast

Play Episode Listen Later Sep 4, 2024 36:21


In episode 76 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah travel to Indiana University in Bloomington to visit Sarah Beggs, Senior Vice President at the Indiana University Foundation. Tune in as Sarah shares how cancer became personal for her family as her daughter faced a stage 4 ALK+ lung cancer diagnosis.

From The Bee Hole End - The Burnley Podcast
Episode 60 - Ins and - mainly - outs, Sunderland preview and ticketing woes

From The Bee Hole End - The Burnley Podcast

Play Episode Listen Later Aug 22, 2024 49:40


It's been a busy old week at Turf Moor with the departures of Berge, Zaroury and Obafemi and the arrival of Humphreys and Worrall so there's plenty for the pod squad to discuss. Is this the ALK model in action? Where will it end? Is there more to come? Simon, Woody, Chris and Justin try to make sense of it all.Plus, Sunderland preview and Justin's ticketing woes. Hosted on Acast. See acast.com/privacy for more information.

Lung Cancer Update
Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer

Lung Cancer Update

Play Episode Listen Later Aug 21, 2024 61:23


Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.

Oncology Today with Dr Neil Love
Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Aug 20, 2024 61:23


Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/InsideTheIssue2024/ALKPosNSCLC).

Commander Sphere
Avatar: The Last Airbender with ALK Alters

Commander Sphere

Play Episode Listen Later Jul 23, 2024 84:57


Talkin' ATLA with ALK! This has been one of our most requested topics and up until now it was exclusive to $10+ members of the patreon! Now it's free to the public. Enjoy!

Oncology Brothers
How to Treat Non-Small Cell Lung Cancer with Actionable Mutations with Dr. Balazs Halmos

Oncology Brothers

Play Episode Listen Later Jul 18, 2024 26:13


Welcome to the Oncology Brothers Podcast! Join Drs. Rahul & Rohit Gosain in this episode as they welcome Dr. Balazs Halmos, a thoracic medical oncologist from Montefiore-Einstein Comprehensive Cancer Center, to discuss the current landscape of metastatic non-small cell lung cancer with actionable mutations in first-line settings. In this informative episode, they cover a wide range of topics including the importance of NGS testing, treatment options for various actionable mutations such as EGFR, ALK, ROS1, RET rearrangements, and more. Dr. Halmos provides valuable insights into decision-making processes, sequencing treatments, and managing toxicities associated with targeted therapies. Don't miss out on this insightful discussion that sheds light on the rapidly evolving space of precision medicine in lung cancer treatment. Stay informed and learn how identifying and targeting specific mutations can optimize treatment outcomes and improve patient quality of life. Tune in to the Oncology Brothers Podcast for expert insights and discussions on the latest developments in oncology. Subscribe now to stay updated on their informative episodes!

NewsWare‘s Trade Talk
NewsWare's Trade Talk: Thursday, July 18

NewsWare‘s Trade Talk

Play Episode Listen Later Jul 18, 2024 21:01


S&P Futures are positive this morning with gains in tech shares. Earnings are in focus today, last night report from TSM was positive, company raised guidance which is helping elevate the sector. this morning. Airline sector is weak as UAL & ALK guided lower yesterday. After the bell today NFLX is expected to report. Odds of President Biden leaving the race have increased over the last 24 hours. Also seeing earnings beats from ASML, JNJ, CFG & USB in the pre-market. Multiple Fed speakers today (Goolsbee, Logan & Daly) which will be their last comments before the July Fed meeting. In Europe, markets are higher ahead of an ECB announcement on monetary policy. Market anticipates two more rate cuts from the ECB this year. Oil prices are ticking lower as oil gives back some of yesterday's gains.

Healthcare Unfiltered
ASCO Updates in Lung Cancer With Balazs Halmos and Lecia Sequist

Healthcare Unfiltered

Play Episode Listen Later Jul 9, 2024 53:13


Drs. Balazs Halmos and Lecia Sequist delve into the groundbreaking updates from the 2024 ASCO Annual Meeting. With Chadi, they reveal game-changing insights on EGFR-mutated lung cancer from the LAURA trial, small-cell lung cancer upgrades from the ADRIATIC trial, important revelations in ALK mutation research, innovative combination therapies, ctDNA results from the ADAURA trial, and conclude with the relevance of the KRYSTAL-12 study. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Oncology Brothers
Lung Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Joshua Sabari

Oncology Brothers

Play Episode Listen Later Jun 12, 2024 24:49


In this episode, hosts Drs. Rahul and Rohit Gosain are joined by special guest Dr. Joshua Sabari, a thoracic medical oncologist from NYU Langone Health. Together, they dive into the highlights from ASCO 2024, focusing on key studies in lung cancer. Here's a quick summary of what you can expect in this episode: •⁠  ⁠LAURA Trial: Discussing the use of Osimertinib as a consolidation approach after chemoradiation in unresectable stage 3 non-small cell lung cancer patients with common EGFR mutation. •⁠  ⁠MARIPOSA Study: Exploring the potential of Amivantamab and Lazertinib in common EGFR mutations. •⁠  ⁠CROWN Study and other ALK inhibitors: Alectinib, Lorlatinib, and Brigatinib for metastatic non-small cell lung cancer. •⁠  ⁠ADRIATIC Study: Examining the use of Durvalumab after concurrent chemoradiation in limited-stage small cell lung cancer. •⁠ PALOMA-3 Trial: Discussing subcutaneous Amivantamab vs. IV Amivantamab with Lazertinib Join the Oncology Brothers and Dr. Sabari as they break down these practice-changing studies and provide insights into the latest advancements in lung cancer treatment. Don't miss out on this informative and engaging discussion! Stay tuned for more ASCO 2024 highlights and updates on GI, GU, and breast cancer in the upcoming episodes. Subscribe to the Oncology Brothers Podcast for the latest in oncology news and research. Thank you for listening! Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Motley Fool Money
From The Frozen Tundra To The Beach

Motley Fool Money

Play Episode Listen Later Dec 4, 2023 31:21


A proposed merger between Alaska Airlines and Hawaiian Airlines could help Alaska take market share over time. (00:21) Jason Moser and Deidre Woollard discuss: - The possibility of the Alaska Airlines and Hawaiian Airlines deal going through. - If airlines lose specialness as they grow. - The race to bring GLP-1 drugs to market. (18:35) Deidre Woollard chats with Solo Brands CEO John Merris about the company's collection of brands and where it could be headed next. Companies discussed: HA, ALK, AMZN, DTC, PFE, RHHBY Claim your dividend stocks here: www.fool.com/dividends Host: Deidre Woollard Guests: Jason Moser, John Merris Producer: Mary Long Engineers: Dan Boyd, Desiree Jones Learn more about your ad choices. Visit megaphone.fm/adchoices